We were unable to classify the risk of BRAF and MEK cardiotoxicity according to the Heart Failure Association (HFA)-International Cardio-Oncology Society (ICOS) tool as the patient did not have echocardiography or cardiac markers examined before the start of treatment of the melanoma. This evidence concerns the gene MAP2K7 and heart failure.